MIRM: Commercial growth, pipeline catalysts, and global expansion position the business for continued momentum

Strong Q2 revenue and raised guidance reflect robust commercial growth, especially for LIVMARLI in rare liver diseases. Multiple near-term clinical milestones, commercial team expansion, and international growth are expected to drive further momentum.Based on Mirum Pharmaceuticals, Inc. [MIRM] H.C…